« Return to News | Technology Solutions

Greenphire opens London office to facilitate expansion in Europe

Wednesday, May 8, 2013 10:38 AM

Greenphire, a provider of payment technologies for the clinical trials industry, has expanded into the European market with the opening of its London office. This addition is a key part of the 2013 strategic plan and is designed to support the increasing global demand for Greenphire’s products and services.

The expansion reflects the commercial and operational success Greenphire has enjoyed in the last two years. Both global payment technology platforms for patient and investigator payments have seen increased adoption within the life sciences industry and the new office in London will play a critical role in continuing to build on the growth Greenphire has experienced.

“We are excited to execute on this key part of our 2013 strategic plan,” said Sam Whitaker, founder and CEO of Greenphire. “Establishing our presence in Europe allows us to support our enterprise clients in those areas where they conduct research and development, facilitates stronger support of the many clinical investigators conducting research on behalf of biopharmaceutical companies and provides a base from which we can grow our commercial presence in Europe.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.